Does TOCILIZUMAB Cause Type v hyperlipidaemia? 8 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Type v hyperlipidaemia have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.0% of all adverse event reports for TOCILIZUMAB.
8
Reports of Type v hyperlipidaemia with TOCILIZUMAB
0.0%
of all TOCILIZUMAB reports
0
Deaths
1
Hospitalizations
How Dangerous Is Type v hyperlipidaemia From TOCILIZUMAB?
Of the 8 reports, 1 (12.5%) required hospitalization.
Is Type v hyperlipidaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does TOCILIZUMAB Cause?
Drug ineffective (32,342)
Rheumatoid arthritis (20,652)
Pain (18,384)
Off label use (18,256)
Arthralgia (15,536)
Joint swelling (14,831)
Fatigue (13,802)
Rash (12,327)
Drug intolerance (11,952)
Contraindicated product administered (11,547)
What Other Drugs Cause Type v hyperlipidaemia?
SACUBITRIL\VALSARTAN (25)
ASPIRIN (24)
CARVEDILOL (23)
ATORVASTATIN (22)
RAMIPRIL (22)
ALENDRONATE (21)
DAPAGLIFLOZIN (21)
ALLOPURINOL (19)
EPLERENONE (19)
EZETIMIBE (19)
Which TOCILIZUMAB Alternatives Have Lower Type v hyperlipidaemia Risk?
TOCILIZUMAB vs TOCILIZUMAB-AAZG
TOCILIZUMAB vs TOCOPHEROL
TOCILIZUMAB vs TOFACITINIB
TOCILIZUMAB vs TOFERSEN
TOCILIZUMAB vs TOLNAFTATE